Last Updated on October 17, 2024 by The Health Master
The US health regulator has pulled up drug maker Lupin for manufacturing lapses, including failure to establish adequate written procedures for cleaning equipment, at its Maharashtra-based plant.
In a warning letter, the US Food and Drug Administration (USFDA) pointed out various lapses at the Tarapur (Thane) plant, which produces active pharmaceutical ingredients (APIs).
“This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API),” the US health regulator said.
It further said, “Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API is adulterated…”
The USFDA inspected the manufacturing facility from March 22 to April 4, 2022.
In the warning letter, the health regulator pointed out the company’s “failure to establish adequate written procedures for cleaning equipment and its release for use in the manufacture of intermediates and APIs.”
It also pointed out a failure on the part of the plant management to establish written procedures to monitor the progress and control the performance of processing steps that may cause variability in the quality characteristics of intermediates and API.
The USFDA also said the plant administration failed to investigate all critical deviations.
“We acknowledge your commitment to suspend the production of drugs for the US market. “In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future,” it said.
If the company plans to resume manufacturing drugs for the US market, notify this office before resuming operations, it said.
“USFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP.”
“We may re-inspect to verify that you have completed corrective actions to any deviations,” USFDA said.
It further stated, “The warning letter notifies you of our findings and provides you an opportunity to address the above deficiencies.”
After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence.”
USFDA issues warning letter to Aurobindo Pharma for manufacturing lapses at API plant
USFDA gives warning letter to Aurobindo Pharma for API facility
Lupin gets warning letter from USFDA for Somerset facility
USFDA issues warning to Shilpa Medicare for cGMP violations
USFDA issues warning letter to Shilpa Medicare, Telangana
Panacea Biotec gets warning letter from USFDA for Baddi facility
NPPA to consider Retail Price Fixation of this Asthma Drug Combination
USFDA approves Ketorolac Tromethamine injection
300 Drug Formulations to have mandatory Bar Codes
USFDA gives final approval for Sodium Phenylbutyrate tablets
IPC clarifies on uniformity of dosage units & impurities in IP 2022
USFDA gives approval for Glycopyrrolate injection
NPPA panel recommends retail price fixation for Atorvastatin and Bempedoic acid
USFDA gives final approval for Mesalamine extended-release capsules
NPPA fixes price of 272 new drugs in the first six months of 2022-23
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
